Federico Rojo

Research interests

Publications

• ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer

  Annals of Oncology · 2023 · https://doi.org/10.1016/j.annonc.2023.05.008

• Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer

  npj Breast Cancer · 2020 · 10.1038/s41523-020-0156-0

• Targeting stromal remodeling and cancer stem cell plasticity overcomes chemoresistance in triple negative breast cancer

  Nature Communications · 2018 · 10.1038/s41467-018-05220-6

• Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer

  Seminars in Cancer Biology · 2017 · https://doi.org/10.1016/j.semcancer.2017.10.003

• Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer

  Cancer Research · 2017 · 10.1158/0008-5472.can-16-2717

• Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non–Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors

  Advances in Anatomic Pathology · 2017 · https://doi.org/10.1097/pap.0000000000000161

• Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research

  Advances in Anatomic Pathology · 2017 · https://doi.org/10.1097/pap.0000000000000162

• A SNAIL1–SMAD3/4 transcriptional repressor complex promotes TGF-β mediated epithelial–mesenchymal transition

  Nature Cell Biology · 2009 · 10.1038/ncb1905

• Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer

  Journal of Clinical Investigation · 2008 · 10.1172/jci34739

• Dose- and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus: A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid Tumors

  Journal of Clinical Oncology · 2008 · https://doi.org/10.1200/jco.2007.14.5482

• High TGFβ-Smad Activity Confers Poor Prognosis in Glioma Patients and Promotes Cell Proliferation Depending on the Methylation of the PDGF-B Gene

  Cancer Cell · 2007 · https://doi.org/10.1016/j.ccr.2006.11.023

• 4E-Binding Protein 1: A Key Molecular “Funnel Factor” in Human Cancer with Clinical Implications

  Cancer Research · 2007 · https://doi.org/10.1158/0008-5472.can-07-0881

• Expression of p95HER2, a Truncated Form of the HER2 Receptor, and Response to Anti-HER2 Therapies in Breast Cancer

  JNCI Journal of the National Cancer Institute · 2007 · https://doi.org/10.1093/jnci/djk134

• Phase II and Tumor Pharmacodynamic Study of Gefitinib in Patients with Advanced Breast Cancer

  Journal of Clinical Oncology · 2005 · https://doi.org/10.1200/jco.2005.08.326

• Combined Epidermal Growth Factor Receptor Targeting with the Tyrosine Kinase Inhibitor Gefitinib (ZD1839) and the Monoclonal Antibody Cetuximab (IMC-C225)

  Clinical Cancer Research · 2004 · 10.1158/1078-0432.ccr-04-0870

• Phase I Study of the Humanized Antiepidermal Growth Factor Receptor Monoclonal Antibody EMD72000 in Patients With Advanced Solid Tumors That Express the Epidermal Growth Factor Receptor

  Journal of Clinical Oncology · 2003 · 10.1200/jco.2004.05.114

• TACE is required for the activation of the EGFR by TGF‐α in tumors

  The EMBO Journal · 2003 · 10.1093/emboj/cdg111

• ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells.

  PubMed · 2003

• Pharmacodynamic Studies of the Epidermal Growth Factor Receptor Inhibitor ZD1839 in Skin From Cancer Patients: Histopathologic and Molecular Consequences of Receptor Inhibition

  Journal of Clinical Oncology · 2002 · 10.1200/jco.2002.20.1.110

• Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 Is Generally Well-Tolerated and Has Activity in Non–Small-Cell Lung Cancer and Other Solid Tumors: Results of a Phase I Trial

  Journal of Clinical Oncology · 2002 · 10.1200/jco.2002.03.038

• PKB/Akt mediates cell-cycle progression by phosphorylation of p27Kip1 at threonine 157 and modulation of its cellular localization

  Nature Medicine · 2002 · 10.1038/nm759

• Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor Types

  Journal of Clinical Oncology · 2002 · 10.1200/jco.2002.03.100

• NH(2)-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer.

  PubMed · 2002

• Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells.

  PubMed · 2001

• Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments.

  PubMed · 2001

Current projects

No projects listed.